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Abstract
Background: Type 1 narcolepsy (NT1) is characterized by symptoms believed to represent Rapid Eye Movement
(REM) sleep stage dissociations, occurrences where features of wake and REM sleep are intermingled, resulting in
a mixed state. We hypothesized that sleep stage dissociations can be objectively detected through the analysis of
nocturnal Polysomnography (PSG) data, and that those affecting REM sleep can be used as a diagnostic feature for
narcolepsy.
New Method: A Linear Discriminant Analysis (LDA) model using 38 features extracted from EOG, EMG and EEG
was used in control subjects to select features differentiating wake, stage N1, N2, N3 and REM sleep. Sleep stage
differentiation was next represented in a 2D projection. Features characteristic of sleep stage differences were estimated
from the residual sleep stage probability in the 2D space. Using this model we evaluated PSG data from NT1 and
non-narcoleptic subjects. An LDA classifier was used to determine the best separation plane.
Comparison with existing methods: This method replicates the specificity/sensitivity from the training set to the
validation set better than many other methods.
Results: Eight prominent features could differentiate narcolepsy and controls in the validation dataset. Using a
composite measure and a specificity cut off 95% in the training dataset, sensitivity was 43%. Specificity/sensitivity was
94%/38% in the validation set. Using hypersomnia subjects, Specificity/sensitivity was 84%/15%. Analyzing treated
narcoleptics the Specificity/sensitivity was 94%/10%.
Conclusion: Sleep stage dissociation can be used for the diagnosis of narcolepsy. However the use of some medications
and presence of undiagnosed hypersomnolence patients impacts the result.
Keywords: Narcolepsy, Diagnostic, Sleep Stage Dissociation, Machine learning, LDA
classifier
2016 MSC: 60G35 92C55 94A12
1. Introduction
Type 1 narcolepsy, a disorder caused by a loss of hypocretin neurons, is diagnosed based on the presence of
daytime sleepiness, cataplexy, and a positive Multiple Sleep Latency Test (MSLT). The MSLT is a 4 to 5 daytime nap
test opportunity where sleep latency and the occurrence of REM sleep within 15 minutes of onset is noted in each
test, a feature called a Sleep Onset REM Period (SOREMP). The MSLT is performed following a night of nocturnal
polysomnography (PSG) , a procedure mostly performed to exclude confounding sleep disorders and note for the
presence of a nocturnal SOREMP, a highly predictive diagnostic feature.
The cause of hypocretin cell loss in narcolepsy type 1 is likely of autoimmune origin. The disorder is strongly
associated with HLA-DQB1*06:02, and has been shown to be triggered by upper airway infections such as
streptococcus and influenza-A, notably 2009H1N1 [1] [2]. Documentation of low cerebrospinal fluid hypocretin 1
(csf-hcrt-1) below 110 pg/ml, is regarded as a definitive diagnostic test for diagnosing narcolepsy type 1 [3] [4].
Preprint submitted to Journal of neuroscience methods February 11, 2017
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The MSLT gained popularity due to the fact that it is quite specific (≈ 97%) and sensitive (≈ 93%) in diagnosing Type
1 narcolepsy [5] [1]. Until recently, a mean sleep latency (MSL) 8 min, and 2 SOREMPs during the daytime naps
were considered as diagnostic for narcolepsy. Based on recent findings that a nSOREMP is highly specific (≈ 99%) for
type 1 narcolepsy, but has only moderate sensitivity (≈ 45%), the most recent classification of sleep disorders (ICSD3)
revised the definition of a positive MSLT to include the nSOREMP as part of the 2 SOREMP requirement. At the
practical level, this change is insignificant, as in our study of over 800 type 1 narcoleptic patients all subjects with a
nSOREMP also had 2 SOREMPs during naps [1]. For example, comparing 516 type 1 narcolepsy cases with a similar
number of age matched controls, specificity for the ICSD3 defined PSG-MSLT was 98.6% and sensitivity 93.3%
versus 98.6% and 92.9% for the older definition [1].
Because a nSOREMP is highly specific (≈ 99%) for narcolepsy but has only modest sensitivity (≈ 40 − 50%), it has
been proposed that other diagnostic biomarkers should be sought within the PSG to add sensitivity, so that a nocturnal
PSG alone could be used to diagnose narcolepsy without the need for a subsequent MSLT. Following on this hypothesis,
sleep onset REM periods during nocturnal sleep, long periods of wakefulness within sleep, or the presence of specific
EEG spectra abnormalities have been found to differentiate narcolepsy versus controls [6] [7]. Unfortunately, however,
none of these new biomarkers were sufficiently predictive alone, although combining them may be helpful and has not
yet been systematically tested. The advantage of using a PSG alone for diagnosis is that widely used to diagnose sleep
disordered breathing, and other sleep disorders, and could thus be used as a screening tool for type 1 narcolepsy.
Using various components of the EEG, EOG and EMG that are known to differentiate sleep stages, it is possible to
artificially project a multi component difference on a 2-D plane that display a clear clustering of the various sleep stage,
a procedure called sleep state space analysis. In essence, a sleep state space analysis displays for any subject how
distinct various sleep stages are from each other. Sleep state space abnormalities has been proposed as a new possible
narcolepsy biomarker based on EEG studies in narcoleptic mice [8]. In this study, Diniz Behn et. al. [8] used a sleep
stage space projection analysis to cluster sleep and wake and shows that narcoleptic mice have less distinct and more
labile states of sleep and wakefulness. Similar work [9] has shown that it is possible to separate human sleep stages and
look at their dynamics in a 2-D space, although these projections did not include stage 1 and did not attempt to study
narcoleptics. Stage 1 may be particularly important to analyze as increased stage 1 is the most consistent difference in
sleep architecture found in patients with narcolepsy [10]. Further, stage 1, REM sleep and wake are the most similar
states at the electrophysiological level. In this study, we expanded on this idea, creating sleep state space projections in
controls and narcolepsy, demonstrating that sleep stage dissociation in patients with narcolepsy (i.e. reduced distance
between sleep stages) can be used to discriminate Type 1 patients from controls and other patients.
2. Population samples used in the study
This section applies the original number of patients in the datasets used in this study. It is important to note that
these dataset have been analyzed by technicians and if the validity of the data were questioned by the technician, the
subject has been removed from the dataset. This section reflects the original dataset numbers before removal.
2.1. Stanford sleep cohort (SSC)
This sample is a naturalistic sample of 862 successive patients that were seen at the Stanford Sleep Clinic between
October 1999 and March 2007 at the Stanford Sleep Clinic [11] [12]. Data from the sample only includes 25 patients
with type 1 narcolepsy (none taking sodium oxybate) and other patients with Delayed Sleep Phase (DSP) n=14,
Insomnias n=141, REM Behavior disorders (RBD) n=4, Restless Leg Syndrome (RLS), n=23, Sleep Disordered
Breathing (SDB) n=607 plus 39 subjects suffering from others disorders. Summary statistics for these subjects are
provided in Table 1.
PSGs were all recorded using the Sandman Elite digital sleep software and Sandman SD32+ amplifiers. The recording
was done using the Stanford Sleep Disorder clinic protocol, which is an extension of the AASMs clinical guidelines
in the fact that it records additional respiratory signals with increased precision and processing. It best corresponds
to updated AASM 2012 scoring rule criteria. In total 18 channels of information are recorded: EEG (using 10/20
electrode placement), EOG, EMG (measured on the submentalis muscle but also on the anterior tibialis muscles of each
leg combined into a single EMG channel for both legs), ECG, vibration snoring, breathing effort, airflow, nasal pressure
2
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and oxygen saturation (SpO2). EEG is recorded using the international 10-20 system with a sampling frequency of 256
Hz. EMG, ECG and snoring signals are recorded using a sampling rate of 512 Hz, breathing effort and airflow recorded
with a sampling rate of 64 Hz and SpO2 recorded at 4 Hz. Filtering is done on electrophysiological signal channels by
bandpass filtering in the range of 0.1 Hz and 0.45 times the sample rate. EMG channels are further high pass filtered at
10 Hz. Sleep stage scoring is performed by trained Registered Polysomnographic technicians under the supervision of
board certified sleep disorder specialists at the Stanford Sleep Clinic.
2.2. Wisconsin sleep cohort (WSC)
This sample includes 1522 PSGs from the Wisconsin Sleep Cohort, a longitudinal study of sleep habits and
disorders in the general population [13]. The cohort was established in 1988 from a sample of employees of 4 state
agencies in south central Wisconsin, aged 30 to 60 years. Beginning in 2000, approximately 800 participants enrolled in
the Wisconsin Sleep Cohort were recruited for an MSLT following a PSG study. Summary statistics for the sample are
provided in Table 1. PSGs were all recorded using a Grass model 78 polysomnography machine and scoring performed
using standard criteria at the time based on AASM guidelines. In total 18 channels were recorded including EEG (using
10/20 electrode placement), EOG and EMG. Breathing was measured using respiratory inductance plethysmography,
nasal and oral airflow using thermocouples and SpO2 using pulse oximetry. All signals had been resampled to 100 Hz
from its original sampling rate before it was made accessible in this study without influence from the authors.
2.3. Jazz narcolepsy study sample (Jazz)
PSGs for this sample are all from patients with cataplexy and were obtained from baseline SXB-15 and SXB-22
studies for a sodium oxybate clinical trial conducted by Orphan Medical, now Jazz Pharmaceuticals [14] [15]. These
were scored according to AASM 2004. The sample includes 270 adult patients with Type 1 narcolepsy. Recordings
were all performed prior to sodium oxybate administration but many patients were on centrally acting stimulants or/and
a few on antidepressants. Recordings were performed in 44 sites in the United States, Canada, Czech Republic, France,
Germany, Netherlands, Switzerland and United Kingdom. Recordings featured 16 channels of PSG information with
EEG(using 10/20 electrode placement), EOG, EMG, breathing, nasal and oral thermistors, nasal pressure and SpO2.
All signals were resampled to 100 or 128 Hz depending on patient before it was made accessible for this study. Scoring
was done locally by experts and technicians using AASM recommendations.
2.4. Korean hypersomnia and narcolepsy sample (Korea)
This sample consists of 308 PSG recordings from Korea but information was missing for some patients therefore
these were excluded so only 151 narcolepsy subjects remain.
Recordings were done on Embla system PSG recorders using S7000 and N7000 amplifiers and the Rem Logic software
(v. 3.4 and 3.2). The recordings were set up using the AASM guidelines. In total 40 channels of data was recorded
including 4 EEG channels(placement compared to the central 10/20 electrodes), 2 EOG, channels, chin EMG, 2 leg
EMG, nasal and oral thermistors and SpO2.
EEG, EMG and EOG were all sampled at 1000 Hz. All pressure signals were sampled at 50 Hz and saturation signals
were sampled at either 5 or 10 Hz.
EEG and EOG filtering was done using a high pass filter with cutoff frequency at 0.5 Hz and a low pass filter with a
cutoff frequency at 70 Hz. For chin EMG and leg EMG filtering was done using a high pass filter with 10 Hz as cutoff
frequency and low pass filter with 70 Hz as cutoff frequency.
2.5. Construction of training and validation sets
The datasets used are described in Table 1. Five non-overlapping datasets were created, the first two to create and
validate our 2-D sleep state space model, thereby identifying features differentiating sleep stages, and the next three to
test the feature model in Type 1 narcolepsy versus other subjects. The first sleep state space training dataset included
200 random samples without replacement from the SSC database and 200 random samples without replacement drawn
from the Wisconsin database. This was selected to ensure representation of a diverse set of PSGs, both drawn from
the general population and from sleep clinics. The sleep stage space validation dataset consisted of all remaining
SSC samples, including a few narcoleptic patients. The first narcolepsy-non narcolepsy comparison dataset included
3
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200 subjects drawn from the WSC in comparison to 17 narcoleptic patients extracted from the Jazz Narcolepsy study
sample (all taken from the SXB-15 database which were recorded at only two hospitals therefore minimizing the effect
of inter-scorer variability). None of these subjects were receiving anti-depressants or centrally acting stimulants. It
was used as a training dataset to construct a separation plane that would distinguish narcolepsy versus controls in the
2-D sleep stage plane. The second dataset, used to validate separation variables, was constructed using patients from
the Korean database. In this sample, non Type 1 narcoleptic patients consist of subjects suffering from idiopathic
hypersomnia or type 2 narcolepsy patients (HLA negative or/and hypocretin level < 200 mg/L) while Type 1 narcolepsy
subjects were patients with low hypocretin level (≤110 mg/L) or HLA positivity plus cataplexy. A final dataset
consisted of subjects treated with anti-depressants or centrally acting stimulants, whether population controls (WSC) or
Type 1 narcoleptic(Jazz Narcolepsy study sample SXB-22 featuring the recordings from 42 sites). This dataset was
also used to test the effects of medications on the classifier.
3. Homogenization of datasets
Because datasets were collected using differing filtering set ups and at different sites, a common preprocessing
EEG algorithm was used to ensure that signal content was similar all across. First all signals was resampled to the
lowest frequency of the electrophysiological channels which was 100 Hz then homogenized using an algorithm that
included: (1) an initial 5th order high pass Butterworth filter with a cutoff frequency at 0.2 Hz; this was used to remove
baseline drifting. (2) a 5th order low pass Butterworth filter with a cutoff frequency at 49 Hz; this was done to remove
artifacts such as 50/60 Hz power line interferences and to homogenize data as some of the samples were not collected
past 75 Hz. (3) a zero-phase digital filtering method filtering both in the forward and the reverse direction; this ensured
that phase content was not distorted and no group delay after filtering. (4) Finally, the EEG signal was truncated so that
values above 300 µV was set to a maximum value of 300 µV and values below −300 µV was set to a minimum value of
−300 µV; this was done to minimize outlier effects. It is known that this introduces some artifacts (especially in the
form of DC frequency content) but values outside of this span is not biological signals so this measurement would be
an artifact either way. Furthermore the DC frequency is not utilized in the feature extraction.
For EMG no preprocessing was done as the features extracted from the EMG is purely time series features therefore
filtering would disrupt the stability of the features across subjects. For EOG the features extracted are correlation
outputs after filtering therefore the preprocessing is included in the feature extraction algorithm.
4. Pre processing of hypnograms
AASM guidelines state that each 30 sec epoch is labeled with its most prominent sleep stage. Any scored epoch
can therefore be a mix of different stages, lowering the value of our sleep stage epoch gold standard. To minimize this
effect, 30 sec epochs were split into 15 sec segments as shown in Appendix Fig. 9. Because the 15 sec epoch preceding
or following a sleep transition was most likely to be composed of 2 sleep stages, it was then removed. This ensured that
our gold standard sleep stages were more homogeneous. This was used for all analysis.
Figure 1: Flowchart on the development of datasets.
In this way the sleep stages that were investigated are pure and do not contain content from other sleep stages.
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Table 1: Datasets and their use in the study. Data have been reported in means with their standard error mean unless otherwise noted.
Dataset:
Sleep
Stage Space Model
(Dataset A)
Training sample
(Dataset B)
Validation in
clinical sample
(Dataset C)
Validation in
hypersomnia
sample
(Dataset D)
Validation in
treated sample
(Dataset E)
Controls
SSC: 200
WSC: 200 SSC: 610 WSC: 200 Korean: 68 WSC: 200
Narcoleptics None SSC: 19 Jazz: 17 Korean: 47 Jazz: 113
Age
SSC:47.4± 1.3
WSC:58.8 ± 1.1 SSC: 45.4 ± 0.6
WSC:55.4 ± 1.5
Jazz:54 ± 3.5 28.3 ± 1.5
WSC:58.8
± 1.1
Jazz:
56.8 ± 0.9
AHI(mean)
SSC: 2.75±2,6
WSC: 19.1±0.8 SSC: 0.2 ± 0.1 WSC: 1.7 ± 0.6 2.4 ± 0.6 WSC: 1.6±0.5
PLM SSC: 8.6 SSC:7.33±0.66 N/A N/A N/A
TST(mean)
SSC:
325.8± 2.9
WSC:
357.5± 3.8
SSC:473.3 ± 2.0 WSC: 454.3±4.0Jazz: 474±6.9 476.9±3.3
WSC:462.0±2.9
Jazz: 483±4.1
Rem Lat.
SSC: 120.6 ± 5.3
WSC: 125.2 ±6.2 SSC: 133.19±3.6
WSC:127.8±6.7
Jazz: 64±17.1 86.0±7.4
WSC:105.8±5.3
Jazz: 61±9.0
Sleep Eff. SSC: 76,7 ± 1.3 SSC:77.4 ± 0.5 WSC: N/A 92.6 ± 1.0 N/A
W(%)
SSC: 23 ± 3.4
WSC:20.8 ± 5.1 SSC: 21.9± 2.4
WSC:20.3±4.6
Jazz: 17.1±9.4 9.1±4.4
WSC:24.2±4.8
Jazz:12.7±15.4
N1(%)
SSC:9.2 ± 1.6
WSC:9.0±2.7 SSC: 8.9±1.2
WSC:9.3±2.3
Jazz: 10.6±6.8 8.9±3.3
WSC:10.1±1.6
Jazz: 12.7±3.5
N2(%)
SSC:48.5 ±3.6
WSC:53.2±4.5 SSC: 48.8±2.3
WSC:51.8±5
Jazz: 43.29±12.5 51.7±4.9
WSC:50.7±3.7
Jazz: 45.6±7.1
N3(%)
SSC:4.3 ± 1.9
WSC:4.4±1.7 SSC: 4.5±0.8
WSC:5.9±2.5
Jazz: 8.3±8.7 12.1±3.6
WSC:5.0±2.0
Jazz: 5.0±2.5
REM(%)
SSC:12.8 ± 1.8
WSC:12.4±2.0 SSC: 13.1±1.1
WSC:12.4±2.1
Jazz: 14.7±10,1 18.7±3.2
WSC:13.4±1.9
Jazz: 15.7±3.9
Use:
Used to create
a sleep state
space and to
model sleep
stages differences
in control
patients
Used to establish
classifier boundaries.
Used to verify
the classifier
in a
replication sample.
Used to verify
if the biomarker
can be used to
distinguish
idiopathic
hypersomnia
and narcolepsy
Used to analyze
whether the
biomarker is
still useable
in subjects
receiving
treatment .
5. Methods
This section introduces the methods used during the study. All computations were done using MATLAB R© for
feature extraction (version 2010 was utilized) and for classification (version 2015a was utilized). All data files had been
provided in the EDF format.
5.1. Overall strategy
To define boundaries of sleep stages, a state space model that could separate stages into reasonable clusters was
first developed using 400 controls. The sleep stages were then projected on to this space and a Gaussian Mixture Model
(GMM) was fitted to give it a normal distribution. These distributions were then used as input to an LDA classifier so
that narcoleptic versus control subjects are classified (Fig. 2).
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Figure 2: Flowchart explaining the strategy used, in simple steps. As seen, we first extracted features from the PSGs to create and validate a
sleep-stage space model. Differences in sleep stage distributions were then used as features to classify narcoleptics versus control subjects.
5.2. Determining features predictive of sleep stages and creation of a sleep stage 2-D space
The approach used was similar to that used by Imbach et. al. [9] except that we also included sleep stage N1, which
is essential to the study of narcolepsy considering reported abnormalities in this stage [10]. The LDA projection used
38 features extracted from the each of the 15 sec epoch segments of EEG, EOG and EMG. An LDA projection was
used because it creates a space which has the highest variance between classes and the lowest variance inside classes.
5.2.1. EEG features
Twenty-eight features were extracted from the EEG (using signals from the central derivatives C3-A1 or C4-A2).
Twenty features were simple power spectrum estimates (PSE) in equally spaced bands ranging from 0.2 Hz to 25 Hz.
The bands are calculated using the Welch method with three second windows and a 50% overlap as this allows for
quasi stable EEG signal. Two additional EEG features were derived using power band ratios as described in [9]. These
power band ratios were computed as follows:
PB1 =
P(8.6[Hz] − 19.3[Hz])
P(1[Hz] − 10.9[Hz]) (1)
PB2 =
P(11.5[Hz] − 20.3[Hz])
P(17.9[Hz] − 32.5[Hz]) (2)
An additional two EEG features were derived based on the cumulative sum of the 90th and 95th percentile of the
power spectrum. The three final EEG features were Hjorts parameters for activity, mobility and complexity:
Activity = var( y(n) ) (3)
Mobility =
√
var
(
y(n) dydn
)
Activity
(4)
Complexity =
Mobility
(
y(n) dydn
)
Mobility ( y(n) )
(5)
5.2.2. EMG features
The three features selected were Hjorts parameters for activity, mobility and complexity.
5.2.3. EOG features
Eight features derived from the EOG modality were inspired by the work done in Kempfner et. al. [16]. By taking
the cross correlation of filtered EOG signals, it was possible to discern between different types of eye movements
such as Rapid Eye Movements (REMs) and Slow Eye Movements (SEMs). Table 2 shows the different filter cut off
frequencies used in this modality.
After filtering the different features values were calculated as:
6
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Table 2: Table showing the bandpass filtering cut off frequencies for the different filters used for the EOG feature extraction
Filter 1 Filter 2 Filter 3 Filter 4
0.25 - 5 [Hz] 0.5 - 5 [Hz] 0.75 - 5[Hz] 1 - 5[Hz]
Filter 5 Filter 6 Filter 7 Filter 8
1.25 - 5[Hz] 1.5 - 5[Hz] 1.75 - 5[Hz] 2 - 5[Hz]
rk(n) =
σab(n)√
σaaσbb
(6)
By calculating EOG features as described above, genuine REMs occurring during REM and non REM sleep create
a negative cross-correlation. These are then split into different variables (SEM vs REM) based on slopes. Background
EOG signal is either not or positively correlated and provides zero values.
5.2.4. Feature normalization:
All 38 features were normalized for each patient so that the feature had zero mean and unity variance. To make
sure features generalize forward feature selection was used.
5.3. Sleep stage dissociation modeling in narcoleptic versus controls
Figure 3: Demonstration on how the model sleep stages were created. First the sleep stages was projected onto the state space and then they were
added together and then normalized to probabilities.
For each subject, epochs derived from each sleep stage were filtered with a 30-point hamming window (A 30
point filtering on 15 sec. epochs was used to extend on findings described previously [9] that found that 5 sec. epoch
segments were best filtered using a 10 point Hamming window). This was done to account for within state variability
during the recording. The filtered epochs of each subject were then projected onto the state space and a GMM with
order 1 fitted to the data. This was done so that the distribution within the sleep stage was expressed in probabilities.
Due to the accuracy of the state space noted in section 6.1, probabilities outside the 15th percentile were set to zero so
that stage overlap was minimized in the model. This was done for each sleep stage and averaged across all epochs for
the model dataset as seen in Fig. 3.
Probability features were next extracted from the remaining datasets similarly to the way the 2-D space model was
created. Epochs are first projected onto the 2-D state space plane and GMM fitted to data points for each subjects sleep
7
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stages. Features are then created by subtracting the sleep stage probability matrix of the model from the probability
matrix of each subject as seen in Fig. 4.
pres = psub ject,sleepstage − psleepstageModel (7)
This is done using all model sleep stages giving in total 25 residual probability matrixes. To make it a single
quantity the square sum of the residuals is computed using:
Rp(cs,ms) =
∑
m
∑
n
p2res(cs,ms)m,n (8)
where pres is the residual probability matrix, cs is the current sleep stage and ms is the model sleep stage. When
subtracting the sleep stage model probability matrix from the subjects sleep stage probability matrix a residual
probability matrix is created. A contribution of 1 originates from the subjects sleep stage probability matrix and a
contribution of -1 originates from the subtraction of the sleep stage model probability matrix. Therefore, due to the
squaring operation, if the sleep stages were totally similar, the sum of square residuals would effectively give a zero
and if the sleep stages were totally dissimilar, a maximum value of two will be obtained.
Figure 4: Demonstration on how the features were extracted. The General Mixture Model were fitted to the data points and then subtracted from the
model sleep stage.
5.4. Classifier
A LDA classifier was used to facilitate interpretation as it is then possible to analyze the effect derived from each
individual features. The LDA classifier also gives a linear decision boundary that can be moved by adjusting the cost
of misclassification so that a classifier with any desired specificity can be selected (in this study, we are seeking high
specificity classifiers that will be used in conjunction with previously described markers such as a nocturnal SOREMP).
A forward feature selection algorithm was used to select features with the best effect. It should be noted that subjects
not containing any REM sleep were considered non-narcoleptic subjects. In future work a non-linear classifier could be
implemented but this would be on the cost of losing the biological knowledge obtained from the results.
6. Results
6.1. State space in narcolepsy versus control
Figure 5 shows 1000 random epochs from each sleep stage extracted from the model dataset (Dataset A) and
projected onto a 2-D projection plane using LDA where inner class variance is minimized and between classes variance
is maximized. As can be seen, the state space created gave excellent separation of each individual sleep stage. A
simple LDA classifier achieved an accuracy of 82% for sleep stage classification, a result equivalent to that obtained in
mice using a similar methodology [8]. In Appendix a comparison between the average of the NT1 vs. Controls for
each sleep stage can be seen in Fig. 8
8
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9
Figure 5: Top: The state space is shown with 1000 random sleep stage epochs from each subject projected onto the space. It is seen separation
between classes is good. An LDA classifier yielded an accuracy of 82%. Bottom: The weights from the two components defining the sleep space.
As it is seen the first component is mainly composed of EEG features while the second component also has influences from the EMG and EOG
modalities. This property is valuable for analysis as it is possible to determine how a change in the signal will affect the position in sleep space. E.g.
a change in EEG will mainly adjust the first component while changes in EOG or EMG will only make a positional change on the second component.
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In Fig. 5 and Eqn.(9) the components are described. It is seen that the first component is mainly describing the EEG
modality features, while the second component includes the EOG and EMG modalities. Therefore, all movement along
the first component is describing changes to the EEG while movement along the second component shows changes in
EEG but also changes in the other modalities.
The formula for the two component state space is shown in Eqn.(9) (insignificant values < 95th percentile omitted).
PC1 =

PS E1
PS E2
PS E3
PS E4
PS E5
PS E6
PS E7
PS E8

·

4.78e−3
−1.90e−2
3.38e−2
−3.62e−2
2.49e−2
−1.05e−2
2.34e−3
−2.12e−4

PC2 =

PS E1
PS E2
PS E3
PS E4
PS E5
PS E6
PS E7
PS E8
PS E9
PS E11
PS E18
PS E19
PS E20
PB1
PB2
EEG90thPercentile
EEG95thPercentile
EEGActivity
EEGMobility
EEGComplexity
EMGActivity
EOGFilter1
EOGFilter2
EOGFilter3
EOGFilter4
EOGFilter6

·

−1.0e−3
2.48e−3
−1.52e−3
−1.95e−4
−1.45e−4
8.36e−4
−5.71e−4
1.44e−4
−1.06e−5
1.48e−5
1.42e−5
1.68e−5
1.38e−4
1.18e−4
−9.21e−4
9.06e−4
−4.24e−4
2.51e−4
−1.25e−4
7.27e−5
−3.64e−5
1.53e−5
−3.74e−5
3.71e−5
−2.19e−5
−1.03e−5

(9)
Where PS Ex is the power spectrum estimated in the x’th band as explained in the method section. The EOGFiltery
is the rk(n) value extracted from the y’th filter as explained in the method section.
6.2. Construction of an overall classifier
Training an LDA classifier on the training dataset (Dataset B) containing 728 clinical subjects and 19 untreated
narcoleptics, it is possible to get a classifier that can separate clinical subjects and narcoleptics. To reduce the amount of
features, a forward feature selection algorithm selected the 8 most prominent probability features; these are described in
Table 3. By varying the cost of a misclassification, the classifier is trained so that a linear separation plane is described
by an equation. If this equation yields y ≥ 0, the subject is classified as narcoleptic. The ROC curve generated by
varying the cost can be seen in Fig. 6. As noted in the introduction a high specificity (> 95%) is required, therefore an
optimal separation plane is chosen and described by Eqn.(10). This is the separation plane used to create the confusion
matrixes in Fig. 6 and the plane is also marked on the ROC curves.
y =

Rp(W,N2)
Rp(W,N3)
Rp(N1,N1)
Rp(N1,N3)
Rp(N2,N2)
Rp(N3,N3)
Rp(REM,N1)
Rp(REM,N2)

·

−10.3
12.2
−5.5
−15.2
−3.5
1.7
4.8
12.6

(10)
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Table 3: Table summarizing the prominent probability features that can separate narcoleptics using sleep stage confusion. It is seen that some sleep
stages show higher mismatch and some show higher match when compared.
Higher Mismatch than
in controls with template
Wake compared to N3
N3 compared to N3
REM compared to N1
REM compared to N2
Higher Match than
in controls with template
Wake compared to N2
N1 compared to N1
N1 compared to N3
N2 compared to N2
As seen in Eqn.(10), sleep stage N1 is involved in three out of eight features while the wake sleep stage is involved
in two out of eight. Some features are based on a higher mismatch between sleep stages while others are based on a
higher match. This is seen by analyzing the sign of the weight.
6.3. Testing the classifier in the various datasets
Using the classifier, that was trained on the Training dataset (Dataset B), on the Validation dataset (Dataset C) it is
seen in Fig. 6B that a sensitivity of 38% and specificity of 94% is found. This is the same specificity as was obtained
on the training set. This means that the classifier is valid for both clinical subjects and control subjects obtained from
multiple recording sites. In Fig. 6C a sensitivity analysis is made on the high pretest probability sample of hypersomnia
subjects vs. narcoleptic dataset (Dataset D). It is seen that there has been a drop in both the specificity, which is at
84%, and the sensitivity, which is at 15%, showing that the classifier is not performing well when the control group is
consisting of hypersomnia patients.
6.3.1. Analysis of the effect of anti-depressant and central acting stimuli
Other work [6] suggests that antidepressants and other central acting stimuli can have an effect on the results of
classification. Therefore, an analysis was done on Dataset E that contained controls versus the narcoleptics receiving
antidepressants and other central acting stimuli. In Fig. 7 it is seen that the introduction of antidepressants and other
central acting stimuli reduces the specificity to 94% and sensitivity to 10%. Therefore, a drop in results is seen when
stimuli is introduced.
7. Discussion
In this study, we explored whether sleep-wake state dissociations could be used to diagnose narcolepsy using
a night time PSG study alone, extending on studies of other PSG biomarkers such as SOREMS [1], sleep stage
transitions [6] and power spectrum ratios [17] in the disorder. Using a combination of EEG, EOG and EMG features,
we created a sleep state space that can be used to distinguish sleep stages in a 2 D-plan. The sleep state of each
narcolepsy patient and each control was next match to this template, and similarities/dissimilarities based on 8 most
distinguishing features were computed into a weighted score that varied from X to Z, with y≥0 being the threshold
for defining narcolepsy. In essence, we are looking at variation to a control template of the various sleep stages in
narcolepsy versus controls.
7.1. Feature analysis
Distinguishing narcolepsy features found following this analysis are summarized in Table 3. Four features were
based on the observation of higher sleep stage mismatch with the template and four features were based on a higher
match with the template. Starting with wake, this state shows mismatch with sleep stage N3, i.e. it has moved away
from N3 of controls but increased match with stage N2, suggesting wake in narcolepsy has moved closer to stage N2.
This result is in line with prior findings showing increased delta and theta activity and decreased alpha and sigma
activity in the wakefulness of narcolepsy patients [18] pointing towards a general lowering of frequencies. This may
11
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Figure 6: A: Shows ROC curve and confusion matrix from the training dataset (Dataset B) using 10-fold cross validation, B: Shows ROC curve and
confusion matrix from the first validation dataset (Dataset C), C: Shows ROC curve and confusion matrix from the second validation dataset (Dataset
D).
also reflect decreased muscle activity in wake. Regarding stage N1, a higher match was observed with template control
N1 and N3 stages. This observation may be interpreted in several ways. First, the N1 sleep stage is known to be
significantly increased in narcoleptic patients, representing about 21.5% of sleep versus 10.3% in controls [19]. The
higher amount of N1 may lead to a more diffuse and variable N1 state than in controls that encompass more similarities
with N3. Second, the higher match observed between the N1 of narcoleptic and template N3 sleep stage may reflect
decreased slow wave activity during N1 in narcolepsy [20]. The narcoleptic N2 sleep stage is only matched with the
model N2 sleep stage. This finding can also be explained by the change in amount of sleep as the percentage increase
in N1 in narcoleptics comes from this stage meaning that there is less variability in N2. Finally, REM sleep stage is
having a higher mismatch with N1 and N2 which could be due to multiple factors as reported by Mukai et. al. [21]
who found power spectral density changes in the 0.3-0.9, 1.5-3.4 and 4.0-4.9 Hz frequency range of REM sleep in
narcolepsy. Other factors, such as the lack of atonia in REM sleep [22], could also have an influence.
7.2. Strength and weaknesses of the study
The study has several strengths and a number of weaknesses. In term of strengths, exploration and validation were
done in distinct datasets and yet gave similar performance. The sensitivity/specificity of this novel combined biomarker
12
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Figure 7: ROC and confusion matrix from the dataset containing the narcoleptics that are receiving anti depressants or other central acting stimuli.
is also quite good, approximately 40% and 95% in the exploration and validation dataset, although it behaved slightly
worse in the type 1 narcolepsy versus other hypersomnia dataset (not surprisingly as this dataset may contain some
mild spectrum narcolepsy cases). A weakness of the study pertains to the difficulties in interpreting the results, as
similarities and dissimilarities are multifactorial in the model. For example, we have not discussed the potential role of
REMs versus Slow Eye Movements (SEMs) in mediating the component diagnostic features discussed above, although,
a comparison between lucid dreamers and narcoleptics found no difference in the EOG characteristics [23]. Further,
because it is most discriminatory of sleep stages, the component examined are mostly influenced by EEG rather than
by other modalities (EOG and EMG). It may be that examining other component projections would yield better results
if abnormalities are more complex than simple sleep-stage mixing, which seems to be the case based on the complex
results obtained. In summary, we found that sleep stage dissociation metrics as projected on a 2-D space can be used
as a biomarker for the diagnosis of NT1 with a specificity of 95%, 94% and a sensitivity of 94% and 38% in the
exploratory and confirmatory dataset. When tested on a dataset compiled of narcoleptics and other hypersomnias,
specificity and sensitivity fell to 84% and 15%, but it is likely cases contain some undiagnosed Type 1 narcolepsy
without cataplexy it is also worth knowing that only this dataset was diagnosed using lumbar punctures and this also
introduces some variation compared to the MSLT diagnosis of the other datasets. Use of antidepressants or stimulants
decreased performance.
7.3. Dataset manipulation
To conduct a study of this magnitude, including datasets recorded at multiple sites, on different equipment and
scored by multiple people sometimes even using different criteria, required a huge normalization to make the datasets
comparable without loss of data characteristics. This will always have an effect on the results. However as multiple
scorings were not available for the data, an interscorer reliability analysis could not be performed to mitigate these issues.
7.4. Future work
This study expands on a collection of features that can be extracted from nocturnal PSGs to diagnose narcolepsy,
namely nocturnal SOREMPS [1], sleep stage transition abnormalities [6] [24] [25], EEG spectral analysis differences
[7] REM sleep atonia [3] and others. A major goal of the next study will be to combine these biomarkers together in a
single detector, and to test this detector in a novel, independent sample of untreated subjects.
Another goal would be to conduct a study using datasets with the same quantity of subjects where more of the relevant
clinical information (HLA and hypocretin measurements) was available the solidify the findings according to the
clinical information.
13
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8. Conclusion
Sleep stage dissociation features of narcolepsy can be evaluated using sleep stage space projection. The biomarker
have some diagnostic value. However, the value of the biomarker is decreased in treated patients.
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10. Appendix
Figure 8: A-E: Figures show the average position in the LDA space for the different sleep stages from a subsample of 199 controls and 148
narcoleptics sampled from the clinical controls and the NT1 patients. The distributions on the different LDA components is shown on the axes and
shown combined on the plane. F: shows the location in the state space to enhance the understanding for the reader.
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